The offering will include a 30-day underwriters option for an additional $4.5 million in shares, the San Diego, Calif.-based company said.
The company is developing a cell-based therapy targeting the treatment of acute liver failure, using a cartridge system designed to produce cells that mimic those of a patient’s liver.
Funds from the round will go towards supporting the clinical development of the ELAD system, as well as towards working capital and other general corporate purposes, according to a press release.
Bank of America Merrill Lynch will act as the sole book-runner for the offering, the company said. Vital Therapies expects the offering to close October 28.
In September, Vital Therapies outlined plans for a possible new phase 3 clinical trial to test its ELAD treatment for liver failure in patients with alcohol-induced liver decompensation, according to an SEC filing.
San Diego-based Vital Therapies halted a Phase III clinical trial of the ELADcell-based treatment for liver failure after it failed to meet its primary and secondary endpoints and shut down 2 other studies.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.